FDA Approves New PrEP Drug Ahead of Truvada Going Generic

FDA Approves New PrEP Drug Ahead of Truvada Going Generic

CYBERSPACE  — The U.S. Food and Drug Administration this week approved Descovy as a second PrEP drug for at-risk adults, except for those who have receptive vaginal sex. The announcement arrives ahead of PrEP drug Truvada going generic next year.

“PrEP drugs are highly effective when taken as indicated in the drug labeling and can prevent HIV infection,” said Jeffrey Murray, M.D., M.P.H., deputy director of the Division of Antiviral Products in the FDA’s Center for Drug Evaluation and Research. “This approval provides more prevention options for certain patients at-risk for acquiring HIV and helps further efforts by the FDA and the U.S. Department of Health and Human Services to facilitate the development of HIV treatment and prevention options to reduce new HIV infections.”

Earlier this year, POZ Magazine reported on research that concluded Descovy “is an effective and safer option for PrEP” for gay and bi men and trans women” and “may be a better PrEP alternative for people at risk for kidney problems.”

A generic version of current PreP drug Truvada will be available September 2020; only one company, Teva Pharmaceutical Industries, is allowed to sell it. Gilead Sciences manufactures both Truvada and Descovy.

"The approval of generic versions of meds is usually met with praise because it means significant cost savings to the consumer — and therefore more access to people who need the medicine. But the case of generic Truvada seems to raise more questions than acclaim," wrote POZ earlier this summer.

It’s unclear if access to generic PrEP will result in cost savings and improved access to necessary medication versus "mass exodus to high-cost Descovy," said Tim Horn, the director of medication access and pricing at the National Alliance of State & Territorial Directors.

“Historically,” he told POZ, “when there’s only one generic manufacturer in the field, the price difference is a miniscule 10 percent to 15 percent. The real savings for all purchasers and payers won’t begin until there’s robust generic competition.”

For related information, including healthcare concerns, visit the Free Speech Coalition's Inspire program for adult industry members; learn more about PrEP here.

Image source: POZ Magazine; Gilead Sciences


Copyright © 2024 Adnet Media. All Rights Reserved. XBIZ is a trademark of Adnet Media.
Reproduction in whole or in part in any form or medium without express written permission is prohibited.

More News

Wicked Drops 3rd Installment of Seth Gamble's Erotic Thriller 'Iris'

Wicked Pictures has released the third installment of reigning XBIZ Performer of the Year Seth Gamble's latest feature, "Iris."

Maria Kazi Stars in Latest From Hookup Hotshot

Maria Kazi stars with Nade Nasty in the latest release from Hookup Hotshot.

Cherry Kiss to Direct for MetArt

MetArt has announced that 2021 XBIZ Europas Female Performer of the Year Cherry Kiss will direct for the studio, under its SexArt brand.

LeWood Drops 200th Release for Evil Angel

Director/performer duo LeWood (Francesca Le and Mark Wood) has released its 200th title for Evil Angel.

Lana Wolf Stars in Latest Release From Immoral Productions

British star Lana Wolf stars with Brad Knight and Matt Bird in a new Euros-themed three-part release from Immoral Productions.

Summer Vixen Stars in 'Endgame' From VMG

Summer Vixen stars with Christian Clay in "Endgame," the latest release from Vixen.

Grooby Releases Latest Volume of 'Trans Starlets'

Grooby has released the 17th volume of "Trans Starlets," directed by Radius Dark.

Mimi Malibu Makes Her Brazzers Debut

Italian star Mimi Malibu has made her Brazzers debut alongside Max Fills in "Sneaky Foot Freak."

Brazzers Celebrates 20th Anniversary With All-Star Orgy

Brazzers is marking its 20th anniversary by releasing a 20-person orgy scene featuring an all-star cast.

Clara Mia Toplines Dorcel's 'Idol'

Clara Mia headlines the latest feature from Dorcel, titled "Idol."

Show More